INGENIO, IRCE, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CELLEX, Department 2B, Villarroel 170, 08036, Barcelona, Catalonia, Spain.
Neurodegenerative Diseases Unit, Neurology Service, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Curr Allergy Asthma Rep. 2018 Jun 15;18(8):42. doi: 10.1007/s11882-018-0796-4.
The sense of smell is today one of the focuses of interest in aging and neurodegenerative disease research. In several neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, the olfactory dysfunction is one of the initial symptoms appearing years before motor symptoms and cognitive decline, being considered a clinical marker of these diseases' early stages and a marker of disease progression and cognitive decline. Overall and under the umbrella of precision medicine, attention to olfactory function may help to improve chances of success for neuroprotective and disease-modifying therapeutic strategies.
The use of olfaction, as clinical marker for neurodegenerative diseases is helpful in the characterization of prodromal stages of these diseases, early diagnostic strategies, differential diagnosis, and potentially prediction of treatment success. Understanding the mechanisms underlying olfactory dysfunction is central to determine its association with neurodegenerative disorders. Several anatomical systems and environmental factors may underlie or contribute to olfactory loss associated with neurological diseases, although the direct biological link to each disorder remains unclear and, thus, requires further investigation. In this review, we describe the neurobiology of olfaction, and the most common olfactory function measurements in neurodegenerative diseases. We also highlight the evidence for the presence of olfactory dysfunction in several neurodegenerative diseases, its value as a clinical marker for early stages of the diseases when combined with other clinical, biological, and neuroimage markers, and its role as a useful symptom for the differential diagnosis and follow-up of disease. The neuropathological correlations and the changes in neurotransmitter systems related with olfactory dysfunction in the neurodegenerative diseases are also described.
嗅觉是当今衰老和神经退行性疾病研究的关注焦点之一。在几种神经退行性疾病中,如帕金森病和阿尔茨海默病,嗅觉功能障碍是运动症状和认知能力下降前数年出现的初始症状之一,被认为是这些疾病早期阶段的临床标志物,也是疾病进展和认知能力下降的标志物。总体而言,在精准医学的框架下,关注嗅觉功能可能有助于提高神经保护和疾病修饰治疗策略的成功率。
嗅觉作为神经退行性疾病的临床标志物,有助于对这些疾病的前驱期进行特征描述,制定早期诊断策略,进行鉴别诊断,并可能预测治疗效果。了解嗅觉功能障碍的机制对于确定其与神经退行性疾病的关联至关重要。几个解剖系统和环境因素可能是导致与神经疾病相关的嗅觉丧失的基础或促成因素,尽管与每种疾病的直接生物学联系尚不清楚,因此需要进一步研究。在这篇综述中,我们描述了嗅觉的神经生物学以及神经退行性疾病中最常见的嗅觉功能测量方法。我们还强调了嗅觉功能障碍在几种神经退行性疾病中的存在证据,以及当其与其他临床、生物学和神经影像学标志物结合使用时作为疾病早期阶段的临床标志物的价值,以及作为鉴别诊断和疾病随访的有用症状的作用。还描述了神经退行性疾病中与嗅觉功能障碍相关的神经病理学相关性和神经递质系统的变化。